Muscarinic M1 agonists in the treatment of Alzheimer's disease

被引：30
|
作者：
Korczyn, AD [1 ]
机构：
[1] Tel Aviv Univ, Sackler Sch Med, Sieratzki Chair Neurol, IL-69978 Ramat Aviv, Israel
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2000年 / 9卷 / 10期
关键词：
Alzheimer's disease; cholinesterase inhibitors; cholinomimetics; muscarinic agonists; therapy;
D O I：
10.1517/13543784.9.10.2259
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The treatment of Alzheimer's disease attempts to correct cholinergic deficiency in the brain. In addition to the established, but restricted, efficacy of acetylcholinesterase inhibitors, attempts are being made to develop agents which will stimulate muscarinic receptors directly. This approach is logical and was found efficacious in several animal models of the disease; however none of these agents succeeded in clinical studies. Several reasons might account for this failure, which are discussed, as well as the prospects for the future.
引用
收藏
页码：2259 / 2267
页数：9
相关论文
共 50 条
  • [1] M1 muscarinic agonists as a therapeutic strategy in Alzheimer's disease - M1 muscarinic agonists in Alzheimer's disease
    Fisher, A
    Pittel, Z
    Haring, R
    Brandeis, R
    Bar-Ner, N
    Sonego, H
    Marcovitch, I
    Natan, N
    Mestre-Frances, N
    Bons, N
    [J]. MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 205 - 210
  • [2] M1 muscarinic agonists for treatment of Alzheimer's disease (AD)
    Fisher, A.
    Caccamo, A.
    Oddo, S.
    Billings, L. M.
    Green, K. N.
    Brandeis, R.
    Pittel, Z.
    Barner, N.
    Elkon, H.
    Natan, N.
    LaFerla, F. M.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S3 - S4
  • [3] Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists
    Fisher, A
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 2000, 84 (02): : 101 - 112
  • [4] M1 muscarinic agonists: Their potential in treatment and as disease-modifying agents in Alzheimer's disease
    Fisher, A
    [J]. DRUG DEVELOPMENT RESEARCH, 2000, 50 (3-4) : 291 - 297
  • [5] Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis
    Fisher, A
    Brandeis, R
    Haring, R
    Eshhar, N
    Heldman, E
    Karton, Y
    Eisenberg, O
    Meshulam, H
    Marciano, D
    Bar-Ner, N
    Pittel, Z
    [J]. JOURNAL OF PHYSIOLOGY-PARIS, 1998, 92 (5-6) : 337 - 340
  • [6] M1 muscarinic agonists target major hallmarks of Alzheimer's disease - an update
    Fisher, Abraham
    [J]. CURRENT ALZHEIMER RESEARCH, 2007, 4 (05) : 577 - 580
  • [7] M1 muscarinic Agonists target major hallmarks of Alzheimer's disease the pivotal role of brain M1 receptors
    Fisher, Abraham
    [J]. NEURODEGENERATIVE DISEASES, 2008, 5 (3-4) : 237 - 240
  • [8] Selective M1 muscarinic agonists as potential disease modifiers for Alzheimer disease (AD)
    Fisher, A
    Brandeis, R
    Pittel, Z
    Inestrosa, N
    Farias, G
    Sparks, DL
    Hartmann, T
    Bons, N
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S10 - S10
  • [9] M1 muscarinic acetylcholine receptor in Alzheimer's disease
    Jiang, Shangtong
    Li, Yanfang
    Zhang, Cuilin
    Zhao, Yingjun
    Bu, Guojun
    Xu, Huaxi
    Zhang, Yun-Wu
    [J]. NEUROSCIENCE BULLETIN, 2014, 30 (02) : 295 - 307
  • [10] M1 muscarinic acetylcholine receptor in Alzheimer’s disease
    Shangtong Jiang
    Yanfang Li
    Cuilin Zhang
    Yingjun Zhao
    Guojun Bu
    Huaxi Xu
    Yun-Wu Zhang
    [J]. Neuroscience Bulletin, 2014, 30 : 295 - 307
12345